Haruaki Tomioka

Summary

Affiliation: Shimane University
Country: Japan

Publications

  1. ncbi [Development of antituberculous drugs: current status and future prospects]
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo shi, Japan
    Kekkaku 81:753-74. 2006
  2. ncbi Combined effects of ATP on the therapeutic efficacy of antimicrobial drug regimens against Mycobacterium avium complex infection in mice and roles of cytosolic phospholipase A2-dependent mechanisms in the ATP-mediated potentiation of antimycobacterial hos
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane University School of Medicine, Shimane, Japan
    J Immunol 175:6741-9. 2005
  3. ncbi Present status and future prospects of chemotherapeutics for intractable infections due to Mycobacterium avium complex
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693 8501, Japan
    Curr Drug Discov Technol 1:255-68. 2004
  4. ncbi Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693 8501, Japan
    Curr Pharm Des 12:4047-70. 2006
  5. ncbi Characteristics of suppressor macrophages induced by mycobacterial and protozoal infections in relation to alternatively activated M2 macrophages
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693 8501, Japan
    Clin Dev Immunol 2012:635451. 2012
  6. ncbi Adjunctive immunotherapy of mycobacterial infections
    Haruaki Tomioka
    Department of Microbiology and Immunology, Faculty of Medicine, Shimane University, Izumo, Shimane 693 8501, Japan
    Curr Pharm Des 10:3297-312. 2004
  7. ncbi Effects of picolinic acid on the antimicrobial functions of host macrophages against Mycobacterium avium complex
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane University School of Medicine, Enya cho 89 1, Izumo, Shimane 693 8501, Japan
    Int J Antimicrob Agents 29:460-4. 2007
  8. ncbi Recent advances in antituberculous drug development and novel drug targets
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693 8501, Japan
    Expert Rev Respir Med 2:455-71. 2008
  9. ncbi [Prospects for the development of new antituberculous drugs putting our hopes on new drug targets]
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane University School of Medicine, 89 1, Enyacho, Izumo shi, Shimane 693 8501, Japan
    Kekkaku 85:815-22. 2010
  10. ncbi Development of new antituberculous drugs based on bacterial virulence factors interfering with host cytokine networks
    Haruaki Tomioka
    Department of Microbiology and Immunology, Faculty of Medicine, Shimane University, Izumo, Shimane 693 8501, Japan
    J Infect Chemother 17:302-17. 2011

Collaborators

  • Toshiaki Shimizu
  • Masanori Matsuoka
  • Chiaki Sano
  • Katsumasa Sato
  • Yutaka Tatano
  • Keisuke Sano
  • Shanshan Cai
  • Seiko Yamabe
  • Masako Emori
  • Hajime Saito
  • Ko Yasumoto
  • Velitchka Dimova
  • Miho Hiraki
  • Hideyuki Kawauchi
  • Fusao Ota
  • Tatsuo Gonda

Detail Information

Publications33

  1. ncbi [Development of antituberculous drugs: current status and future prospects]
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo shi, Japan
    Kekkaku 81:753-74. 2006
    ..4. Adjunctive immunotherapy of mycobacterial infections: Toshiaki SHIMIZU, Katsumasa SATO, Haruaki TOMIOKA (Department of Microbiology and Immunology, Shimane University School of Medicine) There is an urgent need to ..
  2. ncbi Combined effects of ATP on the therapeutic efficacy of antimicrobial drug regimens against Mycobacterium avium complex infection in mice and roles of cytosolic phospholipase A2-dependent mechanisms in the ATP-mediated potentiation of antimycobacterial hos
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane University School of Medicine, Shimane, Japan
    J Immunol 175:6741-9. 2005
    ....
  3. ncbi Present status and future prospects of chemotherapeutics for intractable infections due to Mycobacterium avium complex
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693 8501, Japan
    Curr Drug Discov Technol 1:255-68. 2004
    ....
  4. ncbi Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693 8501, Japan
    Curr Pharm Des 12:4047-70. 2006
    ..Using such findings on MTB genome, drug development using quantitative structure-activity relationship may be possible in the near future...
  5. ncbi Characteristics of suppressor macrophages induced by mycobacterial and protozoal infections in relation to alternatively activated M2 macrophages
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693 8501, Japan
    Clin Dev Immunol 2012:635451. 2012
    ..In addition, this paper highlights the immunological and molecular biological characteristics of suppressor macrophages generated in hosts with mycobacterial infections, especially MAC infection...
  6. ncbi Adjunctive immunotherapy of mycobacterial infections
    Haruaki Tomioka
    Department of Microbiology and Immunology, Faculty of Medicine, Shimane University, Izumo, Shimane 693 8501, Japan
    Curr Pharm Des 10:3297-312. 2004
    ....
  7. ncbi Effects of picolinic acid on the antimicrobial functions of host macrophages against Mycobacterium avium complex
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane University School of Medicine, Enya cho 89 1, Izumo, Shimane 693 8501, Japan
    Int J Antimicrob Agents 29:460-4. 2007
    ..These findings suggest that ROIs, RNIs, FFAs and beta-defensin-1 do not play important roles in the PA-induced potentiation of MPhi anti-MAC activity...
  8. ncbi Recent advances in antituberculous drug development and novel drug targets
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693 8501, Japan
    Expert Rev Respir Med 2:455-71. 2008
    ....
  9. ncbi [Prospects for the development of new antituberculous drugs putting our hopes on new drug targets]
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane University School of Medicine, 89 1, Enyacho, Izumo shi, Shimane 693 8501, Japan
    Kekkaku 85:815-22. 2010
    ..tuberculosis, especially those related to mycobacterial virulence, dormancy, and cross-talk with cellular signaling pathways...
  10. ncbi Development of new antituberculous drugs based on bacterial virulence factors interfering with host cytokine networks
    Haruaki Tomioka
    Department of Microbiology and Immunology, Faculty of Medicine, Shimane University, Izumo, Shimane 693 8501, Japan
    J Infect Chemother 17:302-17. 2011
    ..We also highlight the development of antituberculous drugs based on bacterial virulence factors interfering with the host antimycobacterial cytokine network...
  11. ncbi Antimicrobial activity of picolinic acid against extracellular and intracellular Mycobacterium avium complex and its combined activity with clarithromycin, rifampicin and fluoroquinolones
    Shanshan Cai
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693-8501, Japan
    J Antimicrob Chemother 57:85-93. 2006
    ....
  12. ncbi Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane Medical University, Izumo, 693 8501, Shimane, Japan
    Int J Antimicrob Agents 19:139-45. 2002
    ..Similar profiles were seen for the activities of two-drug combinations of clarithromycin or fluoroquinolones with other drugs against intramacrophage MAC isolated from pulmonary and disseminated MAC infections...
  13. ncbi Interaction of antimycobacterial drugs with the anti-Mycobacterium avium complex effects of antimicrobial effectors, reactive oxygen intermediates, reactive nitrogen intermediates, and free fatty acids produced by macrophages
    Keisuke Sano
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693-8501, Japan
    Antimicrob Agents Chemother 48:2132-9. 2004
    ....
  14. ncbi Antimicrobial activities of cinnamyl rifamycin derivatives, T-9 and T-11, against Mycobacterium tuberculosis and Mycobacterium avium complex (MAC) with special reference to the activities against intracellular MAC
    Katsumasa Sato
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane, Japan
    Microbiol Immunol 50:621-3. 2006
    ..The activities of test rifamycins were found to be in the order rifalazil, rifabutin, T-9, T-11, and rifampicin...
  15. ncbi [Novel type of antimicrobial mechanism in host macrophages against mycobacterial infections]
    Toshiaki Shimizu
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane, Japan
    Nihon Hansenbyo Gakkai Zasshi 78:283-91. 2009
    ..These findings suggest that FFAs (especially AA) produced by the enzymatic action of cPLA2 play important roles as antimycobacterial effectors in the expression of M(phi) antimicrobial activity against mycobacterial pathogens...
  16. ncbi Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane Medical University, Izumo, Shimane 693 8501, Japan
    Antimicrob Agents Chemother 46:519-21. 2002
    ....
  17. ncbi Effects of type II alveolar epithelial cells on T cell mitogenic responses to concanavalin A and purified protein derivatives
    Katsumasa Sato
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Japan
    Microbiol Immunol 49:885-90. 2005
    ..Therefore, it appears that A-549 cells suppress T cell mitogenesis by producing some unknown humoral suppressor factors...
  18. ncbi [Prospects for development of new antituberculous drugs]
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane Medical University, 89 1, Enya cho, Izumo shi, Shimane 693 8501, Japan
    Kekkaku 77:573-84. 2002
    ....
  19. ncbi [Adjunctive immunotherapy of mycobacterial infections]
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane University, School of Medicine, Izumo, Shimane, Japan
    Nippon Saikingaku Zasshi 60:445-52. 2005
  20. ncbi [Profiles of the expression of phospholipase A2 family mRNAs by macrophages infected with Mycobacterium tuberculosis]
    Chiaki Sano
    Department of Microbiology and Immunology, Shimane University School of Medicine
    Kansenshogaku Zasshi 78:503-7. 2004
    ..These findings suggest that type IV cPLA2 and type V sPLA2 both play important roles in the FFA-mediated Mphi Cap antimicrobial activity against MTB organisms...
  21. ncbi [Phagocytosis of Mycobacterium leprae down-regulates anti-microbial activity of murine macrophages against Mycobacterium intracellulare]
    Yutaka Tatano
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane, Japan
    Nihon Hansenbyo Gakkai Zasshi 81:175-83. 2012
    ....
  22. ncbi Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium
    Chiaki Sano
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693 8501, Japan
    Int J Antimicrob Agents 37:296-301. 2011
    ..Taken together, these findings indicate that sitafloxacin and moxifloxacin exhibit favourable activities against M. avium in vitro and in vivo...
  23. ncbi Comparative profiles of intramacrophage behavior of Mycobacterium tuberculosis and Mycobacterium avium complex with different levels of virulence
    Keisuke Sano
    Department of Microbiology and Immunology, Shimane Medical University, Izumo, Japan
    Microbiol Immunol 46:483-6. 2002
    ..However, this phenomenon was not observed with MAC, implying less important roles of RNI in the expression of Mphi antimicrobial activity against MAC organisms...
  24. ncbi Type II pneumocytes in the evaluation of drug antimycobacterial activity
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane Medical University, Izumo, Shimane, Japan
    Expert Opin Pharmacother 4:127-39. 2003
    ....
  25. ncbi [Effects of antisense oligo DNA on the antimicrobial activity of reactive oxygen intermediates and antimycobacterial agents against Mycobacterium avium complex]
    Toshiaki Shimizu
    Department of Microbiology and Immunology, Shimane Medical University, 89-1, Enya-cho, Izumo-shi, Shimane 693-8501, Japan
    Kekkaku 78:33-5. 2003
    ....
  26. ncbi Activity of picolinic acid in combination with the antiprotozoal drug quinacrine against Mycobacterium avium complex
    Toshiaki Shimizu
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693-8501, Japan
    Antimicrob Agents Chemother 50:3186-8. 2006
    ..Quinacrine significantly potentiated the anti-MAC activity of PA, suggesting the usefulness of this combination in the clinical control of MAC infection...
  27. ncbi Roles of reactive nitrogen intermediates and transforming growth factor-beta produced by immunosuppressive macrophages in the expression of suppressor activity against T cell proliferation induced by TCR stimulation
    Toshiaki Shimizu
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693 8501, Japan
    Cytokine 30:7-13. 2005
    ..These findings indicate that RNIs, but not TGF-beta, play important roles in the MI-M phi-mediated suppression of TCR signal-induced mitogenesis, as well as Con A mitogenesis, of the target T cells...
  28. ncbi [Prospects for the development of new antituberculous drugs based on the drug targets related to virulence factors interfering with host cytokine networks]
    Haruaki Tomioka
    Department of Microbiology and Immunology, Shimane University School of Medicine
    Kansenshogaku Zasshi 86:715-22. 2012
    ..tuberculosis, especially those related to mycobacterial virulence factors interfering with host cytokine networks, particularly those acting upon intracellular signaling pathways of macrophages...
  29. ncbi Properties of immunosuppressive macrophages generated by Mycobacterium intracellulare infection in M. intracellulare-susceptible and resistant mice
    Yutaka Tatano
    Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Japan
    New Microbiol 33:87-91. 2010
    ..Thus, the bcg gene may be related to the generation of Min-M(phi)s in host mice...
  30. ncbi [Profiles of intracellular expression, distribution, and activation of phospholipase A2 in host macrophages infected with Mycobacterium avium complex]
    Chiaki Sano
    Department of Microbiology and Immunology, Shimane University School of Medicine
    Kansenshogaku Zasshi 81:695-9. 2007
    ..These findings suggest that MAC infection of RAW264.7 MPhs may induce the activation of intracellular cPLA2, translocating it to phagosomes engulfing infected MAC organisms...
  31. ncbi Profiles of the mRNA expression by macrophages infected with Mycobacterium leprae and Mycobacterium avium complex
    Toshiaki Shimizu
    Department of Microbiology and Immunology, Shimane Medical University, Izumo, Shimane 693-8501, Japan
    Int J Lepr Other Mycobact Dis 70:250-9. 2002
    ..leprae and MAC organisms with murine peritoneal M phi s in terms of the activation of signal transduction pathways for expression of some kinds of immunoregulatory cytokines and immunoprotective enzymes...
  32. ncbi Type II alveolar cells play roles in macrophage-mediated host innate resistance to pulmonary mycobacterial infections by producing proinflammatory cytokines
    Katsumasa Sato
    Department of Microbiology and Immunology, Shimane Medical University, Izumo, Shimane 693-8501, Japan
    J Infect Dis 185:1139-47. 2002
    ..Anti-TNF-alpha and anti-GM-CSF antibodies attenuated A-549 cell-dependent inhibition of intramacrophage mycobacteria, indicating their crucial roles in A-549 cell-mediated potentiation of Mphi antimycobacterial activity...
  33. ncbi Effects of secretory leukocyte protease inhibitor on the tumor necrosis factor-alpha production and NF-kappaB activation of lipopolysaccharide-stimulated macrophages
    Chiaki Sano
    Department of Microbiology and Immunology, Shimane Medical, University, Izumo, Shimane 693-8501, Japan
    Cytokine 21:38-42. 2003
    ....